Podcast appearances and mentions of jeff dachis

Part 2 of a 3 part series. We are thrilled to welcome back Jeff Dachis, who was first on episode 26, to discuss his company One Drop and how he empowers people with diabetes to live their best lives. We highly encourage you to listen to this episode, and our Part 1 (ep. 223) in this series, where we dive further into GLP-1 drugs, how they work, their pros/cons, other solutions to improve metabolic health and the economic impact of these drugs. Jeff is the CEO and Founder of One Health, the maker of the One Health continuous glucose monitor purpose built for people with type 2 diabetes. He is also the founder of One Drop, a simple, powerful and convenient mobile platform for managing diabetes, which was born from his own experience. His desire to bring the quantified self movement, wearables, big data and mobile computing to people with diabetes in a simple, fully integrated solution led him to create the One Health and One Drop drop platform.  In this episode we discuss: A high-level overview of how GLP-1 class drugs work to balance blood sugar, help with weight loss and more.  Jeff's personal experience with Mounjaro. How you use GLP-1 class drugs and whether you should make lifestyle changes alongside taking the drug. Side-effects of taking the drug. The new CGM One Health is manufacturing for Type 2 diabetes. This is such a thought provoking episode, don't forget to head on over to YouTube to watch it in video. We'd love to know your thoughts on this topic because it really does impact everyone.  **Please note that the information provided in this podcast is not intended to be a substitute for professional medical advice, diagnosis or treatment that can be provided by your own Medical Doctor.   Helpful links and resources: www.onedrop.today IG: https://www.instagram.com/onedroptoday/ FB: https://www.facebook.com/onedroptoday/ Podcasts we mention: Episode 26: with Jeff Dachis Episode 223: Part 1 in this series --------------------------------------------------------- Need more protein in your day? Check out these amazing, high quality products from Kion, especially their essential amino acids, which we both use daily.   Use code 'ARTOFLIVING' for a discount off your purchase. ----------------------------------------------------------- Ask us a question/make a recommentation We'd love to hear from you! Click here to share your feedback and suggestions. ----------------------------------------------------------- Sign-up for your 15 minute Health Transformation Audit - Click here. ----------------------------------------------------------- Revitalize your body and prepare for summer with our self-guided liver detox, designed to leave you feeling refreshed, energized, and ready to embrace the season ahead! We now have a program where you can do it on your own schedule but still receive all the wonderful support and recipes of the full program.  Register here! ----------------------------------------------------------- Let us help you get to the root cause of your unwanted symptoms. Schedule a 15 minute consultation to discuss at-home functional medicine lab testing here. ----------------------------------------------------------- How can you support our podcast? Apple users, please subscribe and review our show on Apple Podcasts,we make sure to read them all. Android users, please be sure to subscribe to our show on Google Podcasts so that you don't miss any of the action. Tell a friend about The Art of Living Well Podcast® and our community programs. Share your favorite episode on social media and don't forget to tag us @theartofliving_well. Subscribe to our Youtube channel Shop our Favorite Products: https://www.theartoflivingwell.us/products Connect with us on social media: IG: @theartofliving_well FB: theartoflivingwell Get on our list so you don't miss out on announcements, programs and events. You can download our guests' favorite reads here. Learn more about your hosts: Marnie Dachis Marmet Stephanie May Potter

It's In the News.. a look at the top news stories in the diabetes community over the past seven days. This week, The US FDA gives the green light to Dexcom's G7 CGM, Mark Cuban's Cost Plus Pharmacy puts out a survey all about insulin, new studies looking at teens with type 1 and blood pressure as well as CGM and hospitalizations at the VA and much more! Previous episodes on Dexcom's G7: https://diabetes-connections.com/?s=g7 Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story is big news.. Dexcom's G7 gets FDA approval. This device with a shorter, half hour warm up time, with the sensor and transmitter all in one piece was approved for people age 2 and up with all types of diabetes. It was approved as an iCGM as expected, which is good news for the automated systems the G6 currently works with.. much more to come of course, we've done a lot of episodes on the features and design of the G7 so I'd urge you to listen to those if you haven't yet and of course we'll follow up with a new episode with Dexcom as soon as they'll talk to me! XX In other news.. Illinois Attorney General files a fraud lawsuit, accusing Eli Lilly, CVS Pharmacy, Novo Nordisk and several other pharmaceutical companies of artificially inflating the cost of insulin by over 1,000% since the late 1990s. The complaint singles out Eli Lilly in particular, noting the price for a dose of its analog insulin Humalog rose by 1,527% between 1997 and 2018. "Remarkably, nothing about these medications has changed," the complaint states. "Today's $350 insulin is the exact same drug defendants originally sold for $20." The suit also notes that 13% of Illinoisans, about 1.3 million people, live with diabetes, making the pharma companies' alleged monopoly scheme a public health threat. There are several other state and class action suits against the insulin makers going through the courts right now. So far none have landed more than a glancing blow. https://www.courthousenews.com/illinois-attorney-general-sues-over-sky-high-insulin-prices/ XX A new contender, though, might be entering the arena. Mark Cuban's Cost Plus Pharmacy put out a tweet this week asking for feedback on adding insulin to their lower-cost inventory. Quote - Insulin users: we are evaluating a future insulin test program and would like your feedback. If we offered a 90-day supply of a fast-acting insulin (up to 12 vials/8 packs of pens) for $170 incl. shipping, what would you think?” There's a feedback form and I'll link that up in the show notes. https://forms.office.com/Pages/ResponsePage.aspx?id=nlWlyavTPES7xglhq5HvDwx1m5bO2mRDq1ekDvUshMtUNUZBM0dDUTA3RVpUOEY1WVNWVDE4U0JTMiQlQCN0PWcu XX People with diabetes who used glucose lowering drugs prior to getting COVID-19 seem to have fewer COVID-19 related adverse outcomes during hospitalization. The mediations have already been shown, albeit in conflicting findings, to have possible benefits regarding morbidity and mortality among patients with diabetes who become infected with COVID-19. These meds include orals like Metformin as well as injectables like sglt2 inhibitors like Jardiance and Invokana GLP-1 agonists like Ozempic and Trulicity. https://www.ajmc.com/view/glucose-lowering-drugs-may-reduce-risk-of-covid-19-related-adverse-events-in-patients-with-diabetes XX New research about opioids and diabetes. This study says people People with diabetes who underwent surgery had a significantly increased rate of prolonged opioid use (POU) compared to people without diabetes who underwent surgery. 56% higher for people with type 2 and more than 200% higher for those with type 1. This was a big, retrospective, observational study of more than 43,000 people who had operations at a single diverse healthcare system in 2008-2019. The researchers say this shows that in a real-world setting healthcare providers are generally not accounting for individual risk factors when prescribing postoperative opioids. https://www.medscape.com/viewarticle/985068 XX Teens with Type 1 diabetes (T1D) who took bromocriptine, a medication used to treat Parkinson's disease and Type 2 diabetes, had lower blood pressure and less stiff arteries after one month of treatment compared to those who did not take the medicine, according to a small study published in Hypertension, an American Heart Association journal. People with type 1 are at higher risk of high blood pressure and those diagnosed with T1D as children have even higher risks for heart disease. Therefore, researchers are interested in ways to slow down the onset of vascular disease in children with T1D. The study's small size is a limitation. However, the researchers note that further research into bromocriptine's impact on vascular health in a greater number of people with Type 1 diabetes is warranted; they are planning larger trials. https://medicalxpress.com/news/2022-12-parkinson-medication-blood-pressure-teens.html XX CVS is facing a fraud charge with a lawsuit accusing them of deceptive fundraising in a campaign it held for the American Diabetes Association. Prior to each customer's transaction, a checkout screen prompts the customer with several options for pre-selected dollar amounts, as well as an opt-out option, allowing donations to the diabetes association. Yet, the plaintiff alleges, CVS did not forward donations to the diabetes association, but instead applied the donations toward a legally binding $10 million obligation CVS made to the diabetes association. In November, Edward L. Powers, a lawyer for CVS, filed a motion to dismiss the case, challenging the plaintiff and his lawyer on their interpretation of the alleged $10 million “debt.” CVS says they agreed to fundraise from customers and turn over the donations to the diabetes association. After more than three years of fundraising, CVS would make up the difference between the cumulative customer donations and $10 million, according to the motion. The group bringing the suit disagrees and says everyone who made a campaign donations” are entitled to damages. https://www.bostonglobe.com/2022/12/05/metro/tweet-draws-attention-lawsuit-accusing-cvs-fundraising-fraud-checkout-cvs-has-filed-motion-dismiss-suit/ XX Wearing a CGM can keep you out of the hospital.. according to a new study focusing on Veterans Affairs clinics in the US. Wearing a CGM was associated with a lower risk for all-cause hospitalization and mortality in adults with type 1 and type 2 diabetes. This was even though the people with type 2 who received CGM were actually unhealthier [than non-CGM users] according to the researchers, who called the mortality reductions, dramatic. During a presentation at the World Congress on Insulin Resistance, this researcher said: “All of this data suggests that we may need to look at these types of outcomes in a much more serious fashion, because there may be some additional benefits that we didn't appreciate. If true, then maybe CGM use may become more like the SGLT2 inhibitors, and we'll start using them in a much more comprehensive way.” https://www.healio.com/news/endocrinology/20221202/cgm-use-lowers-hospitalizations-may-reduce-mortality-in-type-1-and-type-2-diabetes XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX outed by celebrities, raved about by TikTok users, and advertised by med spas, a new class of drugs for treating diabetes and obesity has exploded in popularity for its weight-loss effects, leading to rippling shortages across several of the medications. Amid the surge in demand, Eli Lilly and pharmacies have started to tighten access to the latest of this type of drug, tirzepatide, focusing on giving it to people with type 2 diabetes, the only population it's authorized for so far. But that's left another set of patients scrambling — people with clinical obesity who turned to the medication as one of their few options for treatment. The class of drugs are GLP-1 receptor agonists, which mimic the effects of a hormone that can help people feel full. Within this group, Novo Nordisk's obesity drug Wegovy and diabetes drug Ozempic have been in short supply for months due to manufacturing issues and increased demand. Lilly's diabetes medication Trulicity has also been in tight supply, according to the drugmaker. That leaves tirzepatide, sold under the name Mounjaro. Lilly said in a statement that the drug is currently not in shortage, but that the company is continuing to monitor availability of competitor therapies and “supply with a focus on access for people with type 2 diabetes.” Related: Patients seeking novel weight loss drugs find a ‘wild west' of online prescribers In October, Lilly made changes to a discount program for the drug, now requiring people to attest they have type 2 diabetes. The coupons allowed patients to get the drug for $25 a month when it would otherwise cost about $1,000. Some pharmacies are also now checking if people have a diabetes diagnosis before filling prescriptions. https://www.statnews.com/2022/12/07/eli-lilly-tightens-access-tirzepatide-mounjaro-diabetes-obesity/ XX XX On the podcast next week.. yale lacrosse player Bri Carrasquillo was diagnosed just after her freshman year. Now she's part of Dexcom U – a new program for college athletes with type 1. Last week's show was One Drop is making a CGM? We'll talk to CEO Jeff Dachis about that. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Jeff Dachis founded One Drop in 2014, after his own type 1 diagnosis. Known for its sleek meter design and more recently for on-demand telehealth services, One Drop is moving into something new. Jeff shares how that includes what they're calling a continuous health sensor. We'll talk about what that term means, how it could help people with diabetes and what Jeff is still really passionate about. More about One Drop: https://onedrop.today/blogs/press-releases/ada2022-cgm-biowearable-sensor-t2d This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*

It's In the News.. a roundup of the top diabetes stories and headlines of the past seven days. This week: the first AID system to use Libre 3 is released, we learn more about Teplizumab, now brand name Tzield, to prevent T1D and how much it may cost. Couple of new research projects about what triggers type 1, a personal story about retinopathy and a player with T1D takes the stage at the World Cup. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX And by my new book “Still The World's Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes” available on Amazon in paperback and for kindle. XX XX The first automated insulin delivery system using the FreeStyle Libre 3 is now authorized in Germany. The mylife YpsoPump and the FreeStyle Libre 3, combined with the mylife CamAPS FX algorithm from CamDiab Ypsomed already launched mylife Loop in partnership with CamDiab in early summer 2022 in several countries. That was with the Dexcom G6. The company now says By enabling the FreeStyle Libre 3 sensor to work with mylife Loop, people with diabetes now have the option of choosing between two sensors, the Dexcom G6 and the FreeStyle Libre 3, and of customising their loop. with other European countries to follow in 2023. The mylife Loop offering is currently available for Android, iOS will follow in the second half of 2023. I spoke with Ypsomed last year, they are partnering with Lilly and plan to bring their pump the US. Right now oly the Dexcom G6 is approved for AID use, so we'll see if we get the same kind of flexibility. https://www.drugdeliverybusiness.com/ypsomed-camdiab-insulin-dosing-abbott-freestyle-libre-3/ XX Really interesting but very early work on protein known as Befa. It's produced by gut bacteria and triggers the division of cells that make insulin. Reserachers at Univesrty of Utah are working on understanding more about how Befa works.. hoping it could help them figure out a way to stimulate beta cell prdocution. The researchers' findings were recently published in the journal Cell Metabolism. The finding suggests that bacterial warfare in the gut can have collateral beneficial effects on the body, boosting the population of cells that can make insulin throughout the lifespan. In the future, Guillemin's team imagines possible therapeutic applications for the finding. For example, proactively fortifying the microbiomes of high-risk infants with BefA-producing bacteria could prevent them from later developing type 1 diabetes. https://scitechdaily.com/profound-implications-new-research-details-the-microbial-origins-of-type-1-diabetes/ XX A new serological test may be pivotal in the search for viral triggers of diseases like diabetes and celiac disease. PepSeq is a technology that allows scientists to test antibody binding against hundreds of thousands of protein targets at one time, instead of testing one at a time. This protocol is laid out in detail in an article published earlier in November in Nature Protocols. It's said to be an important step forward as concerns about bioterrorism, zoonotic diseases and the next pandemic are never far away. Understanding these pathogens will help scientists develop vaccines and track their movement and evolution. "This can help us to better understand the epidemiology of infectious diseases, and it is also empowering us in our search for potential viral triggers for non-infectious diseases like diabetes and celiac disease," Ladner said. https://medicalxpress.com/news/2022-11-serological-viral-triggers-diseases-diabetes.html XX The recent approval of teplizumab – brand name is now Tzield, for the delay of type 1 diabetes by the US Food and Drug Administration is expected to advance efforts to increase screening to cost-effectively identify those at risk for the condition who would be eligible to receive the new treatment. The anti-CD3 monoclonal antibody was approved November 17. In a clinical trial, teplizumab delayed the onset of clinical (stage 3) type 1 diabetes by approximately 2 years, and longer in some cases.. more than 4 years. It is administered by intravenous infusion once daily for 14 consecutive days and is expected to cost in the region of $200,000 for the course of treatment. During an investor call on November 18, Provention Bio chief commercial officer Jason Hoitt said that among the company's "strategic initiatives" were "advancing awareness and screening for autoantibodies in at-risk individuals, and ultimately, routine screening during pediatric well visits for the general population," as well as "[healthcare provider] belief in teplizumab and desire to prescribe it for their patients." Without broad population-based screening, first-degree relatives of people with type 1 diabetes are likely to be the first to be screened and those with stage 2 identified for receipt of teplizumab. Today, that population is estimated at about 30,000 in the United States, Hoitt said, adding, "with this approval we hope that more stage 2 patients can be readily identified so the course of the disease can be changed." https://www.medscape.com/viewarticle/984748 XX A new way to test for pancreatic cancer is being considered a breakthrough. Pancreatic cancer is commonly considered the deadliest of all cancers in part because with few symptoms and invasive testing, it's so difficult to detect. Bluestar Genomics, which has developed a new non-invasive “liquid biopsy” test that uses a blood test. Pancreatic cancer is eight times as common in patients over the age of 50 with a recent diagnosis of type 2 diabetes. Sometimes, new cases of type 2 diabetes may actually be a consequence of early, undetected pancreatic cancer. Bluestar has breakthrough designation from the FDA. It's too soon for doctors to recommend this for everyone with type 2 but those recently diagnosed should ask their doctors. https://www.diabetesdaily.com/blog/theres-a-new-test-for-pancreatic-cancer-heres-why-it-matters-for-type-2-diabetes-706202/ XX Not really news but a lot of social media chatter about a lame diabetes joke this time during Wednesday, the reboot of the Adams Family. Hearing great things about the show but not the diabetes joke. Good time to mention Diatribes d-stigamtize campaign . I'll link up the website, it's an effort to collect stories and to come up with action to fight diabetes stigma. https://www.dstigmatize.org/ XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX Big shout out to friend of the show – and friend of mine – Mike Hoskins. Mike wrote for diabetesmine for many years and still works at the parent company, Healthline. He recently shared a lot of information and feeling about his diabetic retinopathy diagnosis. He goes into detail of what the treatment has been lie, saying that others sharing that with him has helped make it all a bit easier. Its'a wonderful article and I'll link it up in the show notes. https://www.healthline.com/health/my-diabetic-retinopathy-diagnosisXX XX Many of you have probably been following Jodan Morris for many years, but just in case.. the 28-year old professional soccer player was diagnosed at age 9. He's now part of the U.S. Men's National Team that beat Iran this week and moves ahead to the World Cup knock out rounds this weekend. He plays out of Seattle and has started a foundation, Jordan Morris Foundation, to support kids living with Type 1 Diabetes. XX On the podcast next week.. One Drop is making a CGM? We'll talk to CEO Jeff Dachis about that. Last week's show was with therapist JoAnne Robb. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

At the end of the day, the businesses that matter are the ones that are helping people take back their lives by not letting a diagnosis hold them back. Jeff Dachis is CEO and Founder ONE DROP, a business doing just that by helping people navigate chronic health conditions together, ‘One Drop' at a time. With over 20 years driving digital transformation and change, Jeff has a proven track record in envisioning new market opportunities, innovating new solutions, and strategizing competitive positions. Let's dive right into Jeff's insights about diabetes technology and learn what ‘precision health' is all about and how it's taking the market by storm. [00:01 - 05:50] Opening Segment I introduce Jeff Dachis Jeff's background and diabetes experience CEO of One Drop Inspired by his own diagnosis What is One Drop: Bringing people ‘precision health' What it offers that no one else does Data and science driven [05:51 - 11:21]  Storming the Market with Strategic Partnerships Jeff talks about his current work with Bayer Partnering with One Drop Bayer's vision to move beyond pills How One Drop Makes money Bringing the platform to the market Direct to consumer sales Partnering with digital retailers Building a good relationship with Dexcom Seamless flow of data Bringing insights that lead to better choices Jeff shares about moving passed CGM Technology Moving towards ‘precision health' [11:22 - 21:42] Bringing 'Precision Health' to the Market Jeff talks about his current customer base 50% opt in for multiple condition approach People want to monitor everything at all times Whole Person based solutions T1D vs.Type 2 client base Prioritizing meeting the needs of people People are complex, not just patients Jeff's thoughts on Amazon and Apple entering the Digital Diabetes space The consumerization of health and wellness Consumer side vs. medical  Jeff's thoughts on the rise of digital health High function meets low fidelity experience Room for both telehealth and in-person experiences [21:43 - 23:08] Closing Segment Let's talk five to seven years out  Low fidelity experience moving out of the office and into telehealth Real-time precision insights  Making the lab and insights experience open to everyone via mobile Technology is outpacing the health machine complex We're all in this together The introduction of utilizing people's information Final Words  Tweetable Quotes: “My diagnosis was really the aha moment for me when I really thought about how I could not only manage the condition better myself, but potentially help millions of other people manage it.” - Jeff Dachis “We're bringing data and information and insights to people in a way that allows them to act on their day to day biometric telemetry in ways that no other platform really can do.” - Jeff Dachis “We need a whole person solution, not a silo based solution.” - Jeff Dachis Connect with Jeff on https://www.linkedin.com/in/jeffreydachis/ (LinkedIn). Go check out the award winning app at https://onedrop.today/ (https://onedrop.today/).  To know more, you can connect with me, David Kliff onhttps://www.linkedin.com/in/ephraim-glick-8403a465/ ( )https://www.facebook.com/DiabeticInvestor/ (Facebook), https://twitter.com/diabetic_invstr?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor (Twitter), and https://www.linkedin.com/in/david-kliff-78b669b/ (LinkedIn), or email me at dkliff@diabeticinvestor.com. Be sure to visit https://diabeticinvestor.com (https://diabeticinvestor.com) for more insights and real-time analyses on the evolving business of diabetes. Don't be shy, I'd love to hear from you! You can also reach me at 224-715-3761. NOTE*: We are in no way a replacement for real medical professionals. All information in this podcast is obtained through reliable sources. Please be aware of our...

Diabetes is rising worldwide. Today, over 425 million people have diabetes and projections predict that by 2045, there will be 700 million people with this condition. And despite diabetes can be treated, prevented or delayed with diet, physicial activity, medication and regular screening, every year more than 1.6 million deaths are attributed to the condition. Today we are talking to Jeff Dachis, founder, chairman and CEO of One Drop, a company taking a data approach to help people with diabetes to manage and improve their blood-sugar levels through actionable insights. One Drop combines clinical science, advanced AI, and data points to give those with diabetes, high cholesterol, prediabetes, and high blood pressure the opportunity to make changes that last.

Empowering people with the right data to make healthy choices is the present and future of healthcare. Jeff Dachis, CEO & Founder of One Drop, discusses how the industry can make this happen and shares his appreciation of Led Zeppelin.

Ep. 6, Jeff Dachis & Craig Kanarick, the Founders of Razorfish help us kick off 2021 with a bang. We're gonna party like it's 1995. Episode Timeline 4:00 We like to start... at the beginning. 5:05 Jeff and I knew each other growing up. 9:00 A related AGENCY . COM story... 11:50 You could feel convergence happening. 13:00 The Liberal Arts degree turned out to be handy. 14:25 I bumped into the folks at Blender... I bump into Craig. 16:12 By definition we were lucky. 17:30 This was really happening in New York. 19:25 Razorfish... what the heck?! How'd you come up with the name? 23:50 Break the Xerox machine... fill the inkwell with spaghetti sauce and see what happens. 24:40 There was a small group of us that wanted the Internet to be a beautiful place. 27:15 Build the "Thing," not the "Thing about the Thing." 28:30 The time where you didn't have to explain what the "World Wide Web" was. 30:00 When Omnicom made that bet on those 6 companies... It changed the game. 31:25 What was "Holy Crap! We did that!"? ...Building Schwab . com. 35:22 We were at an Omnicom event in London... 36:30 If you want your Website to do that, Division A needs to talk to B. 39:05 Who wanted to have a bunch of failed projects on your roster?! 41:50 How did those early times impact what you do now? 43:30 How did you maintain your culture as you grew? 45:00 Craig, what are you doing today? 47:15 Jeff, how about you? 51:10 Jeff and I would step back a lot to appreciate where we were. 54:20 In Healthtech I feel a similar sense of change.

You are going to be so inspired by today's conversation with Jeff Dachis.  Jeff is the CEO and Founder of One Drop, a simple, powerful and convenient mobile platform for managing diabetes and chronic health conditions, which was born from his own experience. His desire to bring the quantified self movement, internet of things, big data and mobile computing to people with diabetes in a simple, fully integrated solution led him to create the One Drop platform - which won “Best Design” at the LAUNCH 2015 Festival, and has received a Good Design award, the oldest and the most prestigious Global Awards Program for Design Excellence and Design Innovation. Jeff is a digital visionary and a serial entrepreneur. Considered one of the early pioneers in the development of the World Wide Web, Jeff was involved in the creation of the first banner ad, the creation of the first web animation, and has digital work exhibited as part of the San Francisco Museum of Modern Art's permanent collection. Jeff is also the Co-Founder, former CEO and Chairman of Razorfish (acquired by Publicis), the world's largest digital marketing solutions firm, and a company he bootstrapped from his East Village apartment and led it through its successful $55MM IPO.  Now 25 years later, the Company is over 20,000 employees in 100 cities on 5 continents and generates $2 billion in annual sales. Jeff is a Ernst and Young Entrepreneur of the Year winner (NYC 2001) and finalist (Austin 2012); he is also the 2016 recipient of NYU Steinhardt's Distinguished Alumni Achievement Award. In today's conversation we hear about Jeff's personal journey with type 1 diabetes and how that led him to dream-up and create the company One Drop.  We learn how the One Drop app and the glucose meter work together to empower people to engage in self-care and manage their diabetes.  One Drop's gorgeous device is so cool looking it makes customers feel like a "Diabadass." All the products and services they offer are directed to help those with both type 1 and type 2 diabetes. Jeff shares with us everything you need to know about the subscription packages, including how affordable and useful the glucose monitor and related information is to help improve the customer's quality of life. We also discuss today's state of healthcare and the worldwide diabetes problem.  One Drop offers so much support including access to 24/7, 365 days per year health coaching and accountability when you subscribe. They also ship your test strips right to your door. One Drop is also offering their services direct to employers and they have rolled out coaching programs for treating hypertension, high cholesterol, weight-loss and prediabetes, in addition to type 1 and type 2 diabetes.  We wrap up our conversation talking about the healthcare industry as a whole and then finally on mindset and Jeff's incredibly positive attitude that has really paved the way for where he is today.  You can find One Drop at:  https://onedrop.today/ Twitter: https://twitter.com/jeffdachis Facebook: https://www.facebook.com/onedroptoday/ Instagram: https://www.instagram.com/onedroptoday/ You can purchase the One Drop hardware at the Apple Store, Walmart, Best Buy or online at https://onedrop.today/ Special Offer: Get email updates and receive 20% off your first order. Special Offer Take advantage of our special offer with Healing Elements (new clients only). Address: 2290 Como Avenue  St. Paul, MN 55108 Sign up for One FREE Week of Unlimited Classes! Reserve your week online or in store with the promotional code "AOLW”. Note: Week unlimited begins on the date of purchase. Enjoy $15 off your first 60 or 90 minute Massage or Reiki service using code "AOLW15" book online and note the promo code when scheduling or call to book 651-348-6216. Reminder: Don't forget to subscribe to our podcast so that you can uncover strategies, tips and resources from a variety of experts and our own banks of knowledge as you progress on your journey to living well. We'd also love you to leave us a review on iTunes. Please share this podcast with a friend or anyone who you think could benefit from this information. Join our private Art of Living Well Podcast Facebook Community: This is a community where you can directly interact with us and ask us questions and suggest topics for future episodes. Shop our Favorite Products: We are excited to share our new products including a stainless water bottle (for hot/cold beverages), two recipe books and our Minneapolis Healthy Restaurant Guide https://www.theartoflivingwell.us/products Instagram: @theartofliving_well FB: https://www.facebook.com/theartoflivingwellpodcast/ Sign-up for our Art of Living Well Podcast email list. (We promise not to bombard you with email). Marnie Dachis Marmet's Website (Zenful Life Coaching) Stephanie May Potter's Website

"Bayer's $98M co-development-plus-investment in One Drop from August 2020 has yielded its first new product: a highly-personalized, AI-powered digital program aimed at preventing cardiovascular disease. While the solution itself is impressive in terms of its predictive analytics and integration into One Drop's chronic condition precision health platform, what's really remarkable about this milestone is that it demonstrates what's possible when a pharma co and health tech startup are truly aligned as businesses, from R and D to go-to-market. Bayer Pharmaceuticals' CIO and Head of Digital and Commercial Innovation Jeanne Kehren and One Drop's CEO Jeff Dachis take us inside their collaboration, with a very candid conversation about how their two orgs have not only developed a new product here today, but how they've established a solid foundation for a working relationship that's poised to revolutionize chronic care and define a new market around precision health. This episode was originally released October 2021. To learn more about WTF Health, including how to become an underwriting sponsor of its fun, forward-looking conversations, please visit www.wtf.health. Video versions of all these interviews can be found on WTF Health's YouTube Channel: www.youtube.com/wtfhealth"

The post E1022: One Drop CEO & Founder Jeff Dachis helps people with diabetes manage & improve their blood-sugar levels, shares insights on making data actionable, recent strategic partnership with Bayer, issues with US healthcare & potential life-expansion appeared first on This Week In Startups.

The post E1022: One Drop CEO & Founder Jeff Dachis helps people with diabetes manage & improve their blood-sugar levels, shares insights on making data actionable, recent strategic partnership with Bayer, issues with US healthcare & potential life-expansion appeared first on This Week In Startups.

Before he founded global diabetes management platform One Drop, Founder, CEO and diabetes patient Jeff Dachis was tired of feeling like a patient, and wanted to feel more like a ‘diabadass'. So, when he eventually started up the business and designed One Drop's products, patient wellbeing was always right at the heart of everything they did, and now continue to do. After gaining global exposure in the short time since the company was founded, this is a fascinating insight into starting a medical device business with the consumer, or patient, at the heart of it. Learn more about One Drop here: https://onedrop.today/ Follow Jeff on LinkedIn here: https://www.linkedin.com/in/jeffreydachis/ Get involved and contribute to the conversation yourself at cmconversations@charltonmorris.com

One Drop made a name for itself with a beautiful design; this summer it became the only diabetes devices in Apple stores. But founder Jeff Dachis says that the mission goes far beyond looking good. Join the Diabetes Connections Facebook Group! Jeff explains all that One Drop does and shares his frightening diagnosis story. We also talk about his past as an early internet innovator. Order Stacey's Book - The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child with Type 1 Diabetes ----- 00:00 What's on this week? Stacey welcome: Stacey mentions that two episodes ago she profiled Carson Wedding and said that she was the first person to use the DIY Omnipod Loop. As it's hard to determine exactly who's "first" in the DIY crowd (and not really necessary), Stacey corrects that assertion. Interview with Jeff Dachis Tell Me Something Good Stacey shares a story about watching Law & Order with Benny - the episode was an awful one about using insulin in a very weird way. Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone      Click here for Android

When Jeff Dachis was unexpectedly diagnosed with type 1 diabetes in 2013, he was given nothing more than a short conversation with a nurse practitioner, an insulin pen, and a prescription. He was shocked by the life-threatening diagnosis and left with so many questions and concerns that all he could do in those moments was break down. But after a few days, he decided to make a change. With a background in technology, Dachis began brainstorming the ways in which he could obtain all of the data related to his health and new diagnosis, and make use of it in a way that would allow him to make better choices and prevent negative events from happening in the future; this is when One Drop began.   One Drop is a diabetes management platform that uses mobile computing and data science to help people make sense of and utilize their health and lifestyle data in ways that enable them to live their best lives. The app makes it easy for people to enter their data on the One Drop platform, and once they do, that data not only benefits them but the entire community of One Drop users. The One Drop glucose meter is wireless with the ability to automatically sync all glucose data into the One Drop app, automatically track a user's every step, and integrate seamlessly with any wearable fitness tracker on the market. It automatically integrates information such as weight, blood pressure, medication intake, and more.    The One Drop app focuses on accomplishing three goals: harnessing the power of predictive data science to benefit their users, providing dedicated, personal care and coaching to every user, and ensuring an ecosystem of connected devices and supplies. Dachis makes for a fascinating episode, discussing the details of all this and more.    Tune in and check out https://onedrop.today/pages/mobile-app to get the app for yourself.    

Today's Guest: Jeff Dachis | Founder and CEO of One Drop Greg speaks with Jeff Dachis about the waste inherent in the diabetes marketplace, the lack of solutions for people with Type 2 diabetes, why a consumer-facing company has done so much clinical research, and how a startup can apply design principles more common in the technology world to healthcare - and thrive. Important Links: One Drop for Patients: http://onedrop.today One Drop for Employers & Partners: http://results.onedrop.today Jeff's LinkedIn: http://linkedin.com/in/jeffreydachis Jeff's Twitter: https://twitter.com/jeffdachis  For more info about Greg Matthews, visit: http://linkedin.com/in/gdmatthews  For more, visit the DataPoint show page at http://touchpoint.health/shows/datapoint/.

Jeff Dachis is the founder of diabetes management app One Drop and co-founder of Razorfish. On this episode of Starting Out, Dachis discusses his career path, from his days of being a self-described provocateur in downtown New York to starting a new venture after being diagnosed with diabetes.

Jeff Dachis is one of the forefathers of online advertising. As one of the founders of Razorfish, he was there when all of the things that we take for granted now were still being figured out. Today he’s working on bringing personal big data into the health care space, with OneDrop. This interview goes from b-horror movies, to street teams, to managing your own health data. You’ll love it!   This week’s song is my good friend’s newest offering: Post Tenebras Lux by AJ Davila is a great song and you should listen to it right now. Artista: AJ Davila Canción: Post Tenebras Lux Subscríbete a el podcast en iTunes y en otras plataformas de podcasts, dale Like a la pagina de Facebook y sígueme en twitter @pabloiv P.S. Here’s the trailer for There’s nothing out there, the horror movie Jeff was in: https://www.youtube.com/watch?v=LVV0SJ3AJLo  

Jeff Dachis is one of the forefathers of online advertising. As one of the founders of Razorfish, he was there when all of the things that we take for granted now were still being figured out. Today he’s working on bringing personal big data into the health care space, with OneDrop. This interview goes from b-horror movies, to street teams, to managing your own health data. You’ll love it!   This week’s song is my good friend’s newest offering: Post Tenebras Lux by AJ Davila is a great song and you should listen to it right now. Artista: AJ Davila Canción: Post Tenebras Lux Subscríbete a el podcast en iTunes y en otras plataformas de podcasts, dale Like a la pagina de Facebook y sígueme en twitter @pabloiv P.S. Here’s the trailer for There’s nothing out there, the horror movie Jeff was in: https://www.youtube.com/watch?v=LVV0SJ3AJLo  

Shocked at how diabetes was treated in the U.S., Jeff Dachis turned his business acumen toward the type 1 and 2 diabetes world. Now the co-founder of RazorFish is the founder and CEO of One Drop. One Drop is clearly a passion for Jeff and his enthusiasm shows in this episode. One Drop is a diabetes tracking app, a blood glucose meter, a community and a new business model for suppling meters and test strips. Looks like diabetes picked on the wrong entrepreneur! You can show your support for the Juicebox Podcast by checking out this episodes sponsor - The OmniPod insulin delivery system is the worlds only tubeless insulin pump and you can try a free demo today. Show Notes Check out OneDrop.today The Juicebox Podcast will soon be available on Google Play. Subscribe to the podcast on iTunes today! Check out my type 1 diabetes parenting blog Arden's Day Listen to the Juicebox Podcast online Read my award winning memoir: Life Is Short, Laundry Is Eternal: Confessions of a Stay-At-Home Dad Follow Scott on Social Media @ArdensDay @JuiceboxPodcast   Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.

Jenna and Jeff Dachis chat about One Drop, how it's simplifying diabetes, and the lessons Jeff's learned as a founder over the last 20 years. 

SummaryCraig Kanarick was one of the people responsible for the first ever banner ad, which appeared on Oct. 27, 1994 on Hotwired.com. As mentioned in the podcast, there’s no “first” ad, as several were launched in a rotation at the same time. But as mentioned on the podcast, a lot of people like to think of the first ad as this one, for AT&T, which you can see here:And for more information about the “You Will” AT&T campaign, read about it here, or dig this.Craig went on to found Razorfish, along with his childhood friend Jeff Dachis. Razorfish was a pioneering design, technology and advertising studio that brought many large brands and corporations onto the web for the first time. Razorfish was also a pioneer of the web-tech scene in New York City, which has come to be called “Silicon Alley.” Craig is currently the founder of Mouth.com, headquartered in the DUMBO neighborhood in Brooklyn, as is this podcast (thus, the DUMBO-ish picture I chose above). In our conversation, I mention some contentious media coverage that Razorfish received back in the day, in my opinion, painting them as poster-boys for dotcom-era excess. I offer some of those articles for context:New York MagazineWired60 Minutes II See acast.com/privacy for privacy and opt-out information.